drugset / Trial / NCT02576145
A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will assess whether daclizumab impairs the ability of children receiving a kidney transplant to elicit a primary immune response. The anticipated time on study treatment is 1 day, and the target sample size is 82 individuals.
Timeline
- Start
- 2003-04
- Primary completion
- 2006-01
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DT | Unknown | 0.33 unknown | Intramuscular |
| Subject | Daclizumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | KLH | Unknown | 250 ug | Other |
| Subject | KLH | Unknown | 500 ug | Other |
Indications
No indication recorded.